Agarwal N et al. CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2024;Abstract 18.
Agarwal N et al. CYCLONE 1: Abemaciclib in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). AACR 2023;Abstract CT159.
Agarwal N et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2023;Abstract LBA17.
Agarwal N et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. Lancet 2023;402(10398):291-303. Abstract
Aggarwal R et al. Updated progression-free survival from PRESTO: A phase 3 randomized study of androgen annihilation for high-risk biochemically relapsed prostate cancer (AFT-19). AUA 2023;Abstract LBA02-11.
Armstrong AJ et al. The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES. Eur Urol 2023;84(2):229-41. Abstract
Attard G et al. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: Final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol 2023;24(5):443-56. Abstract
Bögemann M et al. Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: Planned subgroup analysis of the phase 3 ARAMIS trial. Eur Urol 2023;83(3):212-21. Abstract
Bossi A et al. Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. ASCO 2023;Abstract LBA5000.
Chi KN et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023;41:3339-51. Abstract
Chi KN et al. Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. ESMO 2023;Abstract LBA85.
Chowdhury S et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol 2023;34(5):477-85. Abstract
Emmett L et al. Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). ESMO 2023;Abstract LBA84.
Fizazi K et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: The phase 3 TALAPRO-2 trial. Nat Med 2024;30(1):257-64. Abstract
Fizazi K et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24(6):597-610. Abstract
Fizazi K et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med 2023;388(8):719-32. Abstract
Fizazi K et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations. ASCO 2023;Abstract 5004.
Freedland SJ et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389(16):1453-65. Abstract
Hussain M et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41(20):3595-607. Abstract
Hussain M et al. Nadir prostate-specific antigen as an independent predictor of survival outcomes: A post hoc analysis of the PROSPER randomized clinical trial. J Urol 2023;209(3):532-9. Abstract
Matsubara N et al. CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer. ESMO Asia 2023;Abstract 284TiP.
Rahbar K et al. Safety and survival outcomes of 177Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior 223Ra treatment: The RALU study. J Nucl Med 2023;64(4):574-8. Abstract
Saad F et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): Final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24(10):1094-108. Abstract
Sandhu S et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). ASCO 2023;Abstract 5005.
Sartor O et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). ESMO 2023;Abstract LBA13.
Shore ND et al. Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial. Genitourinary Cancers Symposium 2024;Abstract 165.
Shore N et al. A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2023;21(2):278-85. Abstract
Shore ND et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.
Shore ND et al. Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide: Subgroup analysis from HERO study in advanced prostate cancer. Adv Ther 2023;40(11):4919-27. Abstract
Smith MR et al. CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). Genitourinary Cancers Symposium 2023;Abstract TPS289.
Sweeney CJ et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): An international, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24(4):323-34. Abstract